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Abstract
Background: In the last five decades, dengue has emerged as one of  the most important infectious diseases, following a 30-fold 
increase in global incidence throughout tropical and sub-tropical regions of  the world. The actual numbers of  dengue cases are 
under-reported and many cases are misclassified.
Objectives: This article describes the epidemiology, pathophysiology, clinical features and management of  dengue. It also ex-
plores the implications of  infection with this flavivirus for Nigeria, and similar countries.  
Methods: The literature search for publications on dengue in West Africa was performed using PubMed, African Journals On-
line (AJOL), Google Scholar, Web of  Science, databases and grey literature to identify all published papers regarding the topic. 
A snowballing strategy was adopted to identify additional publications. 
Results: Recent reports suggest that dengue is a growing public health problem in Nigeria, the magnitude of  which needs to be 
more clearly defined. Nigeria, the most populous country in Africa has an abundance of  the Aedes aegypti mosquito which is 
known  to transmit dengue, Zika, as well as chikungunya (CHIKV) and West Nile viruses. 
Conclusion: This article provides practical suggestions for strengthening the dengue virus control programme in Nigeria. The 
Nigerian health system shares similarities with health systems in many other sub-Saharan countries. Therefore, the practical sug-
gestions provided at the end of  this review are likely to be applicable to many other African countries.
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Introduction
Dengue, also known as ‘breakbone fever’, is the fastest 
spreading vector-borne viral infection transmitted be-
tween humans by the female Aedes aegypti (Ae) mosqui-
to.1-3  The infection is caused by one of  four dengue virus 
serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) 
belonging to the genus flavivirus within the Flaviviridae 
family. The genus flavivirus also includes pathogens that 
cause Zika virus disease, yellow fever and West Nile fe-
ver.4 Dengue virus contains a positive strand RNA with 
a spherical lipid envelope. The RNA genome codes for 
envelope, capsid and membrane structural proteins in 
addition to seven non-structural proteins. Infection with 
any of  the dengue virus sub-types may result either in 
an asymptomatic infection or a febrile illness of  varying 
severity ranging from mild illness to more severe forms 
such as dengue hemorrhagic fever (DHF) and dengue 
shock syndrome (DSS).5,6
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In the last five decades, dengue has emerged as one of  
the most important infectious diseases, following a 30-
fold increase in global incidence throughout tropical and 
sub-tropical regions of  the world.7 The actual numbers of  
dengue cases are under-reported and many cases are mis-
classified. A recent estimate indicates an annual incidence 
of  390 million cases of  which 96 million (24.6%) mani-
fest apparently, with the majority existing as inapparent 
(asymptomatic) infections.3 Dengue poses a risk to 2.5-
3.6 billion people annually in over 125 endemic countries, 
extending to over 120 million travelers to these countries 
and is estimated to cause about 10,000 deaths annually. 
Factors advanced for the extensive global transmission 
of  dengue include rapid population growth, unplanned 
urbanization, increased international travel, agricultural 
development and possible global climate changes.8  Oth-
er contributory factors are ineffective mosquito control 
measures and limited allocation of  resources to public 
health infrastructure.9
This article reviews the literature on dengue with a focus 
on West Africa. It describes the epidemiology, pathophys-
iology, clinical features and management of  dengue. It 
also explores the implications of  this flavivirus infection 
for Nigeria, the most populous country in Africa.  The 
dengue virus shares the same vector with other import-
ant viruses such as Zika, yellow fever and chikungunya. 
Improvements in dengue virus control could potential-
ly influence the control of  these other arboviral diseases 
thereby reducing morbidity and mortality attributable to 
them. The inferences provided at the end of  this review 
are likely to benefit other low-middle income countries 
that share similar socio-demographic and health system 
features with Nigeria.
Search strategy and selection criteria
The literature search for scientific publications on den-
gue in West Africa was performed using PubMed, African 
Journals Online (AJOL), Google Scholar, Web of  Sci-
ence, databases and grey literature to identify all relevant 
published articles on the topic. A snowballing strategy 
was adopted to identify additional publications. The main 
search comprised individual searches using detailed med-
ical subject heading (MeSH) terms for dengue, West Af-
rica and Nigeria combined with terms relevant to dengue 
diagnosis and management. The Boolean operator ‘AND’ 
and ‘OR’ were used to combine and narrow the searches.
Dengue in West Africa and Nigeria 
Among all world regions, West Africa is projected to have 
the fastest-growing population growth rate over the next 
half-century.10  One recent comparison of  dengue risk 
maps of  the African region  describes population growth 
and high rates of  poverty in the coastal stretch of  West 
Africa11 (between Abidjan and Abuja). This population 
projection may promote the expansion in dengue inci-
dence in the region if  severely weakened health systems12 
in West African countries fail to prioritize resources for 
robust surveillance and control of  febrile illnesses includ-
ing dengue.10
Clinical reports of  dengue in Africa date back to 1926 
following an epidemic in Durban, South Africa.13,14 How-
ever, the dengue virus was only isolated from human sera 
in West Africa between1960s and 1970s.15,16  Specifically, 
the dengue virus was first isolated in Ibadan, Western Ni-
geria in 1960.7 Although there have been many reports 
of  isolated outbreaks of  dengue infection in Nigeria af-
ter 1960, it is likely that many outbreaks of  dengue may 
have been neglected, under-recognized or under-reported 
due to a lack of  awareness of  health staff  and unavail-
ability of  diagnostic tools in health institutions.18  Recent 
reports suggest that dengue viruses are a major cause 
of  acute fevers in Nigeria.19,20  To highlight the growing 
importance of  dengue in Nigeria, recent seroprevalence 
surveys conducted in Maiduguri (Northern Nigeria)21 
and in Ilorin (Western Nigeria)9 showed that 10.1% and 
30.8% of  participants respectively, were seropositive for 
dengue subtype-3 virus (DENV-3). Additionally, dengue 
IgM sero-prevalence among febrile Nigerian children in 
South-Western Nigeria has been reported to be 17.2% 
and 30.8% respectively.22,23 These high prevalence figures 
of  symptomatic dengue virus infections and of  dengue 
IgM antibodies are indicative of  potential endemicity of  
dengue and of  the plausibility of  many missed infections 
by frontline health workers. There is also evidence of  high 
vector density in highly populated Nigerian cities.24 These 
findings together suggest that dengue is a growing public 
health problem in Nigeria, the magnitude of  which needs 
to be more clearly defined. The diagnosis of  dengue in Ni-
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geria is further complicated by evidence of  high co-infec-
tion rates of  malaria and dengue. A recent report revealed 
a 10% active dengue co-infection rate among confirmed 
malaria cases in Ibadan, South-Western Nigeria. Further 
assessment of  dengue IgG seroprevalence among malaria 
patients revealed that all the malaria patients in the study 
were positive for dengue IgG, suggestive of  a past den-
gue infection and consistent with endemicity of  dengue 
virus in this area.25 There is a high density of  the Aedes ae-
gypti  mosquito that transmit dengue, yellow fever (YFV) 
and chikungunya in Nigeria, and the same applies to the 
Anopheles mosquito that transmits malaria.26
The vectors, transmission, pathophysiology and 
clinical features 
The vectors of  dengue virus are mosquitoes of  the ge-
nus, Aedes. This genus of  mosquito was originally found 
in tropical and sub-tropical zones, but has now spread to 
all continents excluding Antarctica.27 Aedes aegypti is the 
primary vector, while Aedes albopictus the Asian tiger mos-
quito is considered the secondary vector of  the disease. 
Spread of  mosquitoes of  this genus is largely by man-
made activities (international trade in used tyres, lucky 
bamboo, among others). They breed in transient water 
collections such as waters in tree holes, or in plant leaf  ax-
ils, bamboo stumps, rock pools, and artificial containers 
including tin cans, coconut shells, water storage contain-
ers, discarded vehicle tyres, broken earthen and ceramic 
wares, as well as other water containers around houses.28,29 
Aedes eggs, which can withstand desiccation, are laid sin-
gly on damp substrates just beyond the water line. Hatch-
ing may occur within a few minutes to several weeks, de-
pending on a lot of  intrinsic and extrinsic factors. Unlike 
most other mosquitoes, Aedes mosquitoes are active and 
bite both humans and animals only during the daytime. 
Early mornings and in the evenings, before dusk, mark 
their peak biting periods. They may bite several times be-
fore completion of  a single blood meal. These breeding 
and biting habits of  Aedes aegypti and Aedes albopictus keep 
them in close proximity to man, facilitating disease trans-
mission. Aedes albopictus is highly adaptive and, thus, 
can survive in cooler temperate regions. Its spread is fa-
cilitated by its tolerance to temperatures below freezing, 
hibernation, and ability to shelter in microhabitats. Aedes 
albopictus was originally a South-East Asia mosquito, but 
has spread to North America, Europe and sub-Saharan 
Africa. Its presence was established in Nigeria in 1992 by 
the National Arbovirus and Vectors Research Centre.30 
Infected humans are the main carriers and multipliers of  
dengue, and serve as a source of  the virus for uninfected 
mosquitoes. Patients who are already infected with the 
dengue virus can transmit the infection (for 4–5 days; 
maximum 12 days) via Aedes mosquitoes after their first 
symptoms appear.31 The female Aedes aegypti mosquito 
bites multiple people during each feeding period. After an 
extrinsic incubation period lasting about 4- 10 days, the 
virus enters the salivary glands of  the mosquito, giving 
the infected mosquito the capacity to transmit the virus 
for the rest of  its life.31 Immature dendritic cells in the 
human skin are the first target with subsequent spread to 
regional lymph nodes, liver, spleen as well as peripheral 
blood monocytes.32 
The syndromes produced by the dengue virus are influ-
enced by age and immunological status. With primary in-
fection, the symptoms are very mild in most children and 
range from sub-clinical infection or mild undifferentiated 
febrile syndromes. Secondary infection is associated with 
a dramatic alteration in the pathophysiology resulting in 
a greater propensity to develop severe dengue. Clinically, 
dengue infection may be asymptomatic or manifest with 
an abrupt onset of  fever, headache and malaise 4-5 days 
after the bite. The patient typically defervesces after 4-5 
days of  fever with an accompanying generalized maculo-
papular rash, which signals recovery. Leucopenia may be 
found at this stage with normal platelet count and trans-
aminase values. 
Primary dengue infection induces a lifelong protective 
immunity to the particular serotype, but cross-reactive 
immunity to the other serotypes is only partial and tem-
porary. Interestingly, secondary or multiple dengue virus 
infection has been identified as a major risk factor for 
severe dengue.33 Other risk factors for severe dengue in-
clude viral virulence and host genetic background.33 
For patients who go on to develop DSS, the clinical 
picture differs after defervescence where they develop 
tachycardia, bleeding, central cyanosis with cool, clammy 
extremities. These features have been attributed to a vas-
cular leak which allows plasma extravasation. Activation 
of  the complement and coagulation pathways occur with 
thrombocytopenia and elevated haematocrit.34  Other 
clinical features include severe and continuous abdominal 
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pain, persistent vomiting with haematemesis, hypother-
mia, restlessness and fainting. Patients may die within the 
next 24–48 hours if  appropriate resuscitative measures 
are not instituted rapidly. With appropriate resuscitation, 
other complications such as disseminated intravascular 
coagulation, multiple organ failure, and respiratory failure 
can be averted.34 
Diagnosis
Early diagnosis of  dengue cases is useful in triaging pa-
tients. There are four main methods of  diagnosing dengue 
virus infection in exposed persons: i) virus isolation and 
characterization, ii) detection of  genomic sequence by a 
nucleic acid amplification assay, iii) detection of  dengue 
virus-specific antibodies and iv) identification of  dengue 
virus antigens (glycoproteins). Virus isolation is achieved 
by cell culture which gives the most specific test result.1 
Sera for virus isolation is usually collected in the first 3-5 
days of  fever. Isolation of  the virus depends largely on 
viral load thus limiting the period within which the den-
gue virus can be successfully isolated in patient serum.16,35 
Viral cell culture has low sensitivity, it is a laborious and 
time consuming procedure. Viral identification can be 
done using dengue-specific monoclonal antibodies in im-
munofluorescence and reverse transcription-polymerase 
chain reaction (RT–PCR). 
Serologic assays are relatively inexpensive and easy to 
perform. These characteristics make them the most com-
monly used tests for dengue infection. IgM levels begin 
to rise by the third day of  a primary infection and peak at 
2 weeks after the onset of  fever. IgG is detectable at the 
end of  the first week of  illness and can persist for life. 
ELISA tests can assay for IgM and IgG levels and the Ig-
M:IgG ratio is useful in distinguishing primary from sec-
ondary dengue virus infections. IgM:IgG ratios of  greater 
than 1.2 or 1.4 are indicative of  primary dengue infection 
while IgM:IgG ratios of  less than 1.2 or 1.4 are indicative 
of  secondary dengue infection.36 The potential cross re-
activity of  dengue virus with other flaviviridae when tested 
with serologic assays remains a significant limitation to its 
use. Prior yellow fever vaccination can also give rise to a 
false positive serologic test for dengue virus. The extend-
ed sero-conversion period also gives rise to false negative 
tests.37
The dengue virus antigens in tissues such as the liver, 
spleen and lymph nodes can be identified using an en-
zyme and a colorimetric substrate with antibodies. The 
flaviviruses all produce a glycoprotein called NS1. Tests 
such as antigen-capture ELISA and lateral flow antigen 
detection can be utilized to identify the presence of  these 
glycoproteins in the blood stream.1   The NS1 antigen is 
detectable from days 0-9 after the onset of  symptoms 
though detection appears to be higher in samples collect-
ed up to three days after onset of  symptoms.  The rapid 
dipstick test, the Dengue NS1 Ag Strip (Bio-Rad Labora-
tories, Marnes-la-Coquette, France), is now available and 
this provides results within 15 minutes. The NS1 dipstick 
test has been shown to have a significantly higher sensi-
tivity for primary infections (94.7%) than for secondary 
infections (67.1%; P < 0.001).38,39  The NS1 protein tests 
now appear to be a potential alternative to culture, PCR 
and serology.40
Treatment, prevention and control
There is no specific treatment for dengue fever other 
than supportive measures and judicious fluid therapy.8 In 
severe dengue, maintenance of  the patient's body fluid 
volume is critical.31 If  the patient is appropriately man-
aged during the critical period which is between 48-72 
hours, the likelihood of  death is minimal.41 Early notifi-
cation of  cases of  dengue is vital in establishing a robust 
response to disease outbreaks.
The global strategy for dengue prevention and control 
has five elements: i) vector control, ii) active disease sur-
veillance based on a comprehensive health information 
system, iii) emergency preparedness, iv) capacity building 
and v) vector control research.2 In December 2015, the 
vaccine CYD-TDV (marketed as Dengvaxia®), devel-
oped by the French pharmaceutical company Sanofi, was 
approved for use in Brazil, Mexico and the Philippines.42 
Dengvaxia is a live attenuated tetravalent vaccine43 devel-
oped from the yellow fever virus44 to stimulate the body’s 
immune system into making antibodies against all four 
subtypes of  dengue. The Yellow fever virus and dengue 
virus have the same genus. For Dengvaxia however, the 
virus is genetically engineered to include genes encoding 
for dengue proteins. However, a warning was released by 
Sanofi on Nov 29, 2017, that Dengvaxia could increase 
the risk of  severe dengue in particular circumstances, 
following a review of  the data from the clinical trials.45 
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This led to a suspension of  the dengue vaccination pro-
gramme in the Philippines. Another vaccine candidate the 
Takeda's Tetravalent Dengue Vaccine  (TDV) is currently 
undergoing phase 2 trials.45  A recent article that reviewed 
optimal control strategies for dengue during the outbreak 
in Pakistan described a strong reciprocal relationship be-
tween the use of  insecticide and vaccination; as the cost 
of  insecticide increased the use of  vaccination appeared 
to increase also.46
Implications for Nigeria, and similar countries
1. To complement sporadic reports of  dengue prevalence 
by individual scholars in the country, the Federal Ministry 
of  Health in Nigeria should, as a matter of  urgency, in-
vest in nationwide dengue surveys to determine the mag-
nitude of  different dengue serotypes circulating in Nige-
ria, following which dengue should be made a reportable 
disease in the country. The nationwide dengue surveys 
should run simultaneously with vector surveillance and 
the concomitant virus identification assays, to explicitly 
define the dengue serotypes and their vectors in the coun-
try. A robust and integrated dengue disease surveillance 
system needs to be   established and linked to the national 
health information system, with a set of  core indicators 
which should be monitored.  Outbreak preparedness in-
volving the relevant agencies should be developed as a 
matter of  priority.
2. There is a need for national authorities to strengthen 
dengue fever control strategies as dengue is one of  many 
diseases that is routinely misdiagnosed as malaria and 
thus remains a neglected tropical disease in the country. 
Vector control and education about basic ways of  limit-
ing bites from the vectors of  dengue by use of  protective 
clothing needs to be prioritized. Source reduction is cru-
cial and should include environmental modification strat-
egies such as fitting lids or covers on water containers and 
disposing of  such containers where possible. The use of  
insecticides such as organophosphates (temephos) and 
pyrethroids has been shown to be beneficial though resis-
tance of  both Aedes aegypti and Aedes albopictus to these has 
been described. The use of  genetically modified (GM) 
mosquitoes has been shown to reduce the population of  
disease carrying vectors by 95%.47  The GM mosquitoes 
work by two methods namely, "population replacement" 
in which a mosquito population is substituted by one that 
is unable to transmit pathogens. A bacterial symbiont 
known as Wolbachia has the capacity to infect the mos-
quito and limit its ability to spread other pathogens.  The 
second approach is called "population suppression" and 
this can be achieved by the use of  the Sterile Insect Tech-
nique (SIT) where sterile male mosquitoes are produced 
to mate with wild female ultimately leading to a reduction 
in the mosquito population.48 Such an effective strategy 
should be exploited. Given the rapid unplanned nature of  
urban development and the poor water supply and sew-
age systems in Nigeria44, greater efforts at vector control 
are likely to yield a great impact. The overall benefits of  
vector control are likely to influence the transmission of  
other diseases such as malaria, yellow fever, Zika and chi-
kungunya.
3. We recommend a more comprehensive focus on, and 
commitment to, improved diagnosis of  febrile illnesses49 
in Nigeria. Laboratory surveillance of  dengue is vital as 
this will enhance the identification and confirmation of  
dengue given that malaria, yellow fever, chikungunya and 
dengue may be clinically indistinguishable causes of  fe-
ver.50 The provision of  NS1 dipstick testing for dengue at 
the primary health care level might be a bold step in the 
right direction. The NS1 dipstick test is relatively easy to 
use, it has an acceptable sensitivity and specificity profile 
and provides rapid results. 
4. Building the capacity of  frontline health workers and 
prioritizing dengue as a cause of  fever in our setting is 
critical for success.  An intensive push for health worker 
training and utilization of  clinical algorithms for man-
aging dengue is likely to yield dividends.51  This capacity 
building should be extended to laboratory scientists and 
entomologists to promote rapid and accurate diagnosis 
of  dengue infections across Nigeria while ramping up 
vector identification and control. 
5. In the context of  ongoing concerns over the spread of  
Zika from the Americas to other regions of  the world, 
Nigeria needs to be on the alert for cases of  Zika virus 
disease4, especially as the country is within the dengue 
belt where both the Aedes aegypti (i.e. the vector for both 
dengue and the Zika) and  Aedes albopictus mosquitoes 
abound. Surveillance and monitoring for Zika cases is a 
necessity in addition to appropriate mosquito population 
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control measures. As intrauterine, sexual intercourse, and 
blood-borne spread of  Zika are now proven means of  
transmission, appropriate precautions should be widely 
promoted in our communities.  
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